Brief: Tempest Therapeutics Q3 EPS USD -0.79
05/11/2025 13:53
Nov 5 (Reuters) - Tempest Therapeutics Inc TPST.O: TEMPEST THERAPEUTICS Q3 EPS USD -0.79 TEMPEST THERAPEUTICS Q3 NET INCOME USD -3.511 MILLION TEMPEST THERAPEUTICS Q3 OPERATING INCOME USD -3.597 MILLION Further company coverage: TPST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T